SAN DIEGO, July 17, 2019 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, today
announced that argenx has dosed the first subject in a phase 1
clinical trial evaluating the safety, pharmacokinetics and
pharmacodynamics of efgartigimod (ARGX-113), using Halozyme's
proprietary ENHANZE® drug delivery technology.
"Since the signing of our collaboration with argenx earlier this
year, we have made strong progress and I am delighted that the
first phase 1 trial has been initiated in such a short amount of
time," said Dr. Helen Torley,
President and CEO of Halozyme. "We look forward to expanding our
work with argenx to bring the potential benefits of subcutaneous
administration to more patients suffering from severe autoimmune
diseases through our ENHANZE® technology."
Initiation of this study triggers a $5
million milestone payment to Halozyme during the current
quarter under the global collaboration and license agreement
between the two companies.
About
ENHANZE® Technology
Halozyme's
proprietary ENHANZE® drug-delivery technology is
based on its patented recombinant human hyaluronidase enzyme
(rHuPH20). rHuPH20 has been shown to remove traditional limitations
on the volume of biologics that can be delivered subcutaneously
(just under the skin). By using rHuPH20, some biologics and
compounds that are administered intravenously may instead be
delivered subcutaneously. ENHANZE® may also benefit
subcutaneous biologics by reducing the need for multiple
injections. This delivery has been shown in studies to reduce
health care practitioner time required for administration and
shorten time for drug administration.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug
pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor in animal
models. PEGPH20 is currently in development for the treatment of
several cancers and has the potential to be used in combination
with different types of cancer therapies. In addition to its
proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical companies
including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly,
Bristol-Myers Squibb, Alexion and argenx for its
ENHANZE® drug delivery technology. Halozyme is
headquartered in San Diego. For
more information visit www.halozyme.com.
Halozyme Safe Harbor Statement
In addition to
historical information, the statements set forth above include
forward-looking statements including, without limitation,
statements concerning the possible activity, benefits and
attributes of ENHANZE®, the possible method of action of
ENHANZE®, its potential application to aid in the
dispersion and absorption of other injected therapeutic drugs, and
statements concerning certain other potential benefits of
ENHANZE® including facilitating more rapid delivery of
injectable medications through subcutaneous delivery. These
forward-looking statements also include statements regarding the
product development efforts of Halozyme's ENHANZE®
partner and Halozyme's potential receipt of payments associated
with future collaborative target nominations, achievement of
certain milestones, and royalties on sales of commercialized
products. These forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. The forward-looking
statements are typically, but not always, identified through use of
the words "believe," "enable," "may," "will," "could," "intends,"
"estimate," "anticipate," "plan," "predict," "probable,"
"potential," "possible," "should," "continue," and other words of
similar meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including uncertainties concerning the number of
additional collaborative targets nominated and whether milestones
will be achieved, uncertainties concerning whether collaborative
products are ultimately developed or commercialized, unexpected
delays in the receipt of milestone payments due to Halozyme,
unexpected expenditures and costs, unexpected results or delays in
development and regulatory review, unexpected regulatory approval
requirements, unexpected adverse events and competitive conditions.
These and other factors that may result in differences are
discussed in greater detail in Halozyme's most recent Annual and
Quarterly Reports filed with the Securities and Exchange
Commission. Except as required by law, Halozyme undertakes no duty
to update forward-looking statements to reflect events after the
date of this release.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-announces-first-clinical-dosing-in-argenxs-phase-1-trial-of-efgartigimod-argx-113-with-enhanze-drug-delivery-technology-300886003.html
SOURCE Halozyme Therapeutics, Inc.